Metronidazole Suppositories — Competitive Intelligence Brief

Metronidazole Suppositories (Metronidazole Suppositories) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antibiotic. Area: Infectious Disease.

marketed Nitroimidazole antibiotic Bacterial/protozoal DNA Infectious Disease Small molecule

Target snapshot

Metronidazole Suppositories (Metronidazole Suppositories) — Dongfang Hospital Beijing University of Chinese Medicine. Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and protozoal DNA by generating reactive oxygen species after reduction of its nitro group.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole Suppositories TARGET	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA
Metronidazole Vaginal	Metronidazole Vaginal	Peking University Shenzhen Hospital	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Metronidazole gel 1%	Metronidazole gel 1%	Galderma R&D	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Metronidazole Topical Gel 2%	Metronidazole Topical Gel 2%	Jinnah Postgraduate Medical Centre	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Levornidazole Disodium Phosphate for Injection	Levornidazole Disodium Phosphate for Injection	Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd	marketed	Nitroimidazole antibiotic	Microbial DNA (non-selective; requires anaerobic reduction)
Metronidazole (BQ10)	Metronidazole (BQ10)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole Vaginal Gel 0.75%	Metronidazole Vaginal Gel 0.75%	Balmoral Medical company	marketed	Nitroimidazole antibiotic	Bacterial DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antibiotic class)

1. National Taiwan University Hospital · 2 drugs in this class
2. Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · 2 drugs in this class
3. University of Guarulhos · 2 drugs in this class
4. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
5. LEO Pharma · 1 drug in this class
6. Sherief Abd-Elsalam · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. Appili Therapeutics Inc. · 1 drug in this class
10. bioRASI, LLC · 1 drug in this class